TAK-875

A GPR40 agonist in Phase-III trials, which activates a receptor that stimulates and regulates insulin production, enhancing insulin secretion in response to changes in serum glucose levels. It has little effect on insulin secretion when serum glucose is normal, and may reduce the risk of hypoglycaemia.

References in periodicals archive ?

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

A study comparing the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) in type II diabetes mellitus patients

The oral, highly potent, and selective free fatty acid receptor 1 agonist TAK-875 significantly improved glycemic control in patients with type 2 diabetes without increasing treatment-emergent hypoglycemic events in a phase II, randomized, controlled trial comparing TAK-875, glimepiride, and placebo.

At weeks 4, 8, and 12 of treatment, all of the 303 patients who were randomized to receive treatment with TAK-875 at doses ranging from 6.

25-mg TAK-875 group was smaller than that in the glimepiride group, they noted.

Novel FFARL agonist shows promise for type 2 diabetes

0% by 12 weeks was generally similar in the 25- to 200-mg TAK-875 and glimepiride groups, and changes, relative to the placebo group, were significant, they said.

About 2% and 3% of the TAK-875 patients and the placebo patients, respectively, had treatment-emergent hypoglycemic events during treatment, compared with 19% of the glimepiride patients, and the events were mild to moderate in intensity in all groups.

Novel FFAR1 agonist reduced [HbA.sub.1c] in type 2 diabetes

Burant and his colleagues promise to raise many questions about the potential of TAK-875 in the treatment of type 2 diabetes, according to Dr.

TAK-875 appeared to have no effect on insulin resistance in this study.

Durability, safety questioned

18 October 2011 - Japan's Takeda Pharmaceutical Company Limited (TYO:4502) said today it had commenced a Phase III clinical study programme for its investigational Type 2 diabetes therapy TAK-875.

The programme will be carried out across the US, Latin America, and Europe, Takeda said, noting that TAK-875 is the first GPR40 agonist to reach late stage (Phase III) clinical development.

Takeda begins Phase III study programme for Type 2 diabetes treatment TAK-875

12 September 2011 - Japanese Takeda Pharmaceutical Company Limited (TYO:4502) said today it had advanced TAK-875 into Phase III studies for the treatment of Type 2 diabetes in Japan.

Takeda advances TAK-875 into Phase III studies for Type 2 diabetes treatment

CITE

Site: Follow: Share:

Open / Close